The CIC-backed clinical genomics platform operator took its series B round to $30.1m following a $17.1m extension that will fund the development of automation and statistical analysis functionality.
Congenica, a UK-based clinical genomics software developer backed by Cambridge Innovation Capital (CIC), the patient capital fund affiliated to University of Cambridge, has increased its series B round to £23.3m ($30.1m) with a $17.1m extension led by Parkwalk Advisors.
Parkwalk, the fund management division of commercialisation firm IP Group, was joined in the round by Digital China Health (DC Health) Technologies, a corporate venturing vehicle for IT services group Digital China Holdings.
Unnamed strategic and existing investors were…
